Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives
申请人:Ates Celal
公开号:US20130102794A1
公开(公告)日:2013-04-25
The present invention provides an alternative synthesis of N-substituted aminotetralines comprising resolution of N-substituted aminotetralins of formula (II), wherein R
1
, R
2
and R
3
are as defined for compound of formula (I).
[EN] PROCESSES FOR PREPARING PHARMACEUTICAL COMPOUNDS<br/>[FR] PROCÉDÉS DE PRÉPARATION DE COMPOSÉS PHARMACEUTIQUES
申请人:PLIVA HRVATSKA D O O
公开号:WO2009056791A1
公开(公告)日:2009-05-07
The present invention relates to the preparation of N,N-disubstituted aminotetralins, such as rotigotine, as the free base form or as a pharmaceutically acceptable salt.
[EN] NOVEL ROTIGOTINE SALTS<br/>[FR] NOUVEAUX SELS DE ROTIGOTINE
申请人:PLIVA HRVATSKA D O O
公开号:WO2009063171A1
公开(公告)日:2009-05-22
The present invention relates to new salts of N,N-disubstituted aminotetralins, such as rotigotine hydrobromide p-toluenesulfonate, heminaphthalene-l,5-disulfonate, tartrate, and phosphate. Also provided herein are methods of making the new salts and using them for the treatment of diseases that may be prevented, ameliorated or eliminated by the administration of a dopamine D2 receptor agonist or an antiparkinsonian agent.
[EN] PREPARATION OF CRYSTALLINE ROTIGOTINE BASE<br/>[FR] PRÉPARATION DE ROTIGOTINE À BASE CRISTALLINE
申请人:PLIVA HRVATSKA D O O
公开号:WO2009063170A1
公开(公告)日:2009-05-22
The present invention relates to processes of preparing rotigotine form its heminaphthalene -1,5- disulfonate salt as a free base in solid cyrstalline form.
Process for preparing nitrogen-substituted aminotetralins
申请人:Aderis Pharmaceuticals, Inc.
公开号:US06372920B1
公开(公告)日:2002-04-16
The present invention relates to a process for preparing optically active and racemic nitrogen-substituted 2-aminotetralins of the following Formula (I):
wherein R1, R2, R3, R4, and n are set in the specification, wherein the process comprises alkylating the corresponding unsubstituted 2-aminotetralin of Formula (II):
with a reactant of the Formula (III):
Z—(CH2)n—R3 (III)
wherein Z is a leaving group, in the presence of a base, wherein the base is selected from the group consisting of alkali metal carbonate and alkali metal bicarbonate, and wherein the amount of the base is less than about a 1.9-fold molar excess with respect to the amount of the 2-aminotetralin.